company

Bristol-Myers

BMYBristol-Myers Squibb
CIK 0000014272ticker BMY
as of 2026-07-01
Monitor thisAsk about this
at a glance
Cash $9.6B (as of 2026-03-31)
Revenue $11.5B
30 trials sponsored · 13 assets in the graph
Synthesized from structured facts only — each point cited above.

Financials

SEC EDGAR XBRL · latest period per metric
Cash$9.6B2026-03-31
Ga Expense$1.6B2026-03-31
Net Income Loss$2.7B2026-03-31
Revenue$11.5B2026-03-31
Rnd Expense$2.6B2026-03-31
Stockholders Equity$20.1B2026-03-31
Total Assets$86.5B2026-03-31

Pipeline

13 assets
AripiprazoleHaloperidolOlanzapineRisperidoneXanomeline-trospium (Cobenfy)AripiprzoleEDSS with CO feedback and health checklistEDSS with health checklist feedback alonHealthy volunteersKarX-ECStayersSwitchersfMRI

Recent filings

SEC EDGAR
4open ↗2026-06-16
4open ↗2026-06-05
11-Kopen ↗2026-06-05
11-Kopen ↗2026-06-05
11-Kopen ↗2026-06-05
8-Kopen ↗2026-05-08
S-8open ↗2026-05-08
4open ↗2026-05-05
8-Kopen ↗2026-04-30
10-Qopen ↗2026-04-30
SCHEDULE 13Gopen ↗2026-04-29
DEFA14Aopen ↗2026-04-17

Facts & assertions

8 sourced
Financial Status
profitable
Latest Cash
9,574,000,000
Latest Ga Expense
1,617,000,000
Latest Net Income Loss
2,677,000,000
Latest Revenue
11,489,000,000
Latest Rnd Expense
2,649,000,000
Latest Stockholders Equity
20,068,000,000
Latest Total Assets
86,476,000,000
relationships
The graph out of here
asset
Aripiprazole
small molecule
drug
Haloperidol
small molecule
drug
Olanzapine
small molecule
drug
Risperidone
small molecule
drug
Xanomeline-trospium (Cobenfy)
small molecule
drug
Aripiprzole
small molecule
drug
EDSS with CO feedback and health checklist
BEHAVIORAL
drug
EDSS with health checklist feedback alon
BEHAVIORAL
drug